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Abstract
Hypoxia is a hallmark of many pathological tissues. Macrophages accumulate in hypoxic
sites and up-regulate a range of hypoxia-inducible genes. The matrix proteoglycan versican
has been identified as one such gene, but the mechanisms responsible for hypoxic induc-
tion are not fully characterised. Here we investigate the up-regulation of versican by hypoxia
in primary human monocyte-derived macrophages (HMDM), and, intriguingly, show that
versican mRNA is up-regulated much more highly (>600 fold) by long term hypoxia (5 days)
than by 1 day of hypoxia (48 fold). We report that versican mRNA decay rates are not affect-
ed by hypoxia, demonstrating that hypoxic induction of versican mRNA is mediated by in-
creased transcription. Deletion analysis of the promoter identified two regions required for
high level promoter activity of luciferase reporter constructs in human macrophages. The
hypoxia-inducible transcription factor HIF-1 has previously been implicated as a key poten-
tial regulator of versican expression in hypoxia, however our data suggest that HIF-1 up-
regulation is unlikely to be principally responsible for the high levels of induction observed in
HMDM. Treatment of HMDM with two distinct specific inhibitors of Phosphoinositide 3-ki-
nase (PI3K), LY290042 and wortmannin, significantly reduced induction of versican mRNA
by hypoxia and provides evidence of a role for PI3K in hypoxic up-regulation of versican
expression.
Introduction
Hypoxia (low oxygen tension) is a feature of many pathological tissues. The median oxygen
tension in normal tissues is usually between 20 and 70 mmHg, but in ischemic pathological
sites can be as low as zero mmHg [1]. Such hypoxic areas are found in tumours [2], wounds
[3], atherosclerotic plaques [4], arthritic joints [5], and the retina [6] and ischemic limbs of dia-
betics [7].
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Cells of the monocyte/macrophage lineage are involved in all of the above pathologies.
Monocytes are derived from myeloid stem cells, and following release from the bone marrow
circulate in the bloodstream for 1–3 days before migrating into tissues where they differentiate
into macrophages [8, 9]. Macrophages are phagocytic, and can take up and destroy microor-
ganisms or inhaled microscopic foreign bodies such as smoke, diesel exhaust, and pollen parti-
cles, and also have important roles in innate and adaptive immunity and tissue repair [10, 11]
It has been known for many years that macrophages accumulate in poorly vascularized,
hypoxic sites [12]. Accumulation of macrophages has been reported in avascular, hypoxic and
necrotic sites in breast [13] and ovarian carcinomas [14], wounds [15], atherosclerotic plaques
[16] and arthritic joints [17].
Hypoxic macrophages up-regulate a number of hypoxia-inducible transcription factors, the
most important of which is Hypoxia-inducible factor 1 (HIF-1) [18]. Macrophages are unusual
in that they rely heavily on HIFs for energy generation and activity even under normal oxygen
tensions [19], meaning that they are able to respond rapidly and effectively to the challenges
posed by the need to function in hypoxic sites. Previous studies have shown that many genes
are up-regulated in hypoxic macrophages [20, 21, 22, 23, 24]. The extra cellular matrix (ECM)
proteoglycan versican has been identified as one such hypoxia-inducible gene [25].
Versican is a large aggregating chondroitin sulphate proteoglycan, and occurs in at least
four isoforms [26]. It is found in various sites including the brain [27], and skin [28], and in-
creased expression is observed in sites of tissue injury [29] and in cancers including breast [30],
cervical [31], gastrointestinal tract, prostate [32], brain [33], and melanoma [34]. Several re-
ports have also highlighted the role of versican in wound healing [35, 36] and in vascular dis-
ease, especially atherosclerosis [37, 38]. Versican binds low-density lipoprotein particles, and
accumulation of versican in blood vessel walls is believed to promote extracellular lipoprotein
retention and uptake leading to foam cell formation [39]. In the study which first reported hyp-
oxic induction of versican [25], it was suggested to be regulated, at least in part, by Hypoxia-In-
ducible Factor 1 (HIF-1), the most important hypoxia-inducible transcription factor, which
has been described as the “master regulator” of the transcriptional response to hypoxia.
The aims achieved in this study were to increase understanding of the mechanisms respon-
sible for the up-regulation of versican by hypoxia in primary human macrophages, using pro-
moter reporter deletion constructs, transcription factor over-expression, and gene expression
quantification.
Results
Hypoxia induces versican gene expression in primary human monocyte-
derived macrophages
We investigated the effect of 18h hypoxia (0.2% O2 [1.5 mmHg]) on versican gene expression
in 5-day differentiated primary human monocyte-derived macrophages (HMDM) using Real-
Time RT-PCR. All 13 donors tested showed substantial hypoxic induction of total versican
mRNA (using PCR primers which amplify all mRNA splice variants), however there was con-
siderable variability (average 48 fold induction, range 20–120 fold; Fig 1A). The adherence
method we used to isolate monocytes from blood yields a population of>95% monocyte-mac-
rophages in our hands [18]. However, to confirm macrophages as the principle cell type show-
ing hypoxic up-regulation of versican, we quantified versican induction in macrophages
derived from monocytes isolated using MACS magnetic beads linked to antibodies specific for
the monocyte surface antigen CD14. We compared these to adherence-purified HMDM and to
the CD14-negative fraction of the MACS separation (found to consist of>95% lymphocytes as
assessed by FACS analysis) from the same donors. All cells were incubated 5 days in normoxia
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before being exposed to a further 18h of either normoxia or hypoxia. Hypoxia significantly in-
duced total versican mRNA expression in adherence-purified HMDM and CD14+ monocyte-
derived macrophages but not in lymphocytes (Fig 1B).
While most studies on hypoxia are done with relatively short term exposure (typically 18-
24h), we also wanted to model the behaviour of monocytes entering hypoxic tissue and under-
going differentiation into macrophages under hypoxia, since this is biologically relevant to
pathological conditions in which chronic hypoxia is a feature and we have shown previously
that this produces considerably higher fold induction of the VEGF gene than short term hyp-
oxia [40]. We also wanted to study the effect of long and short term exposure to hypoxia on the
mRNA levels of the different versican mRNA splice variants, which generate the distinct versi-
can protein isoforms, to examine the possibility of differential expression. Monocytes were pu-
rified by adherence, and then cultured for 5 days under normoxia, or 4 days in normoxia
followed by 1 day of hypoxia, or 5 days in hypoxia, as previously described [40]. One day of
hypoxia produced a 30-fold induction of total versican mRNA, markedly less than 5d of hyp-
oxia (637 fold) (Fig 1C). Analysis of the different splice variants of versican mRNA in HMDM
showed that the V2 variant was not detectable, in line with previous findings in macrophages
[41]. The three mRNA variants which were detectable (V0, V1, and V3) showed large average
fold inductions: (20, 36 and 91-fold, respectively) after 1 day of hypoxia. However, after 5d of
hypoxia, the fold inductions for all three variants were much higher (399, 407 and 878 fold re-
spectively) (Fig 1C).
Up-regulation of versican mRNA by hypoxia is not due to increased
transcript stability
To determine whether up-regulation of versican mRNA by hypoxia is due to increased tran-
scription or increased mRNA stability, we investigated the decay of versican mRNA and the
mRNA of a gene known to be transcriptionally induced by hypoxia, Glucose Transporter 1
(GLUT-1), in normoxic and hypoxic primary HMDM (Fig 2). Messenger RNA degradation
was not significantly different between normoxia and hypoxia for either gene, indicating that
the increases in versican mRNA in hypoxic human primary macrophages (Fig 1A–1C) are due
to transcriptional up-regulation rather than increased mRNA half-life.
Fig 1. Up-regulation of versican gene expression by hypoxia in primary humanmacrophages. (A) Real Time RT-PCR quantification of the effect of
18hrs hypoxia (0.2%O2) on versican mRNA in 5-day differentiated HMDM from 13 different donors. Values are hypoxic fold induction relative to normoxia.
(B) Changes in versican mRNA fold induction levels in response to 18hrs of hypoxia (0.2%O2) were quantified by real-time RT-PCR in HMDM, CD14
+
magnetic bead purified monocyte-macrophages and CD14- cells, all incubated for 5d after isolation before being exposed to a further 18h of either normoxia
or hypoxia, in 3 independent experiments using different donors. Values are hypoxic fold induction relative to normoxia. (C) Real-time RT-PCR quantification
of versican mRNA isoforms in HMDM after differentiation either 5d in normoxia (20.9%O2), 4d in normoxia followed by 1d in hypoxia, or 5d in hypoxia (0.2%
O2), in 4 independent experiments using different donors. All data were normalized to 2MGmRNA levels determined by separate PCRs, and are expressed
as mean fold induction (relative to the equivalent normoxic culture) ± SEM, and were analyzed for significance using paired t-tests. **** = p <0.0001, *** = p
<0.001, * = p <0.05.
doi:10.1371/journal.pone.0125799.g001
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Hypoxic up-regulation of versican protein in human primary
macrophages
To investigate whether the hypoxia-induced increases in versican mRNA were matched by in-
creases in versican protein, we analyzed versican protein expression in PBMC—derived macro-
phages after 5 days incubation in normoxia or hypoxia using intracellular staining followed by
flow cytometry [42, 43, 44]. Since versican is exported, all cells were treated with Brefeldin A to
block protein export in order to facilitate quantification by intracellular staining. With this ap-
proach we can demonstrate that hypoxia induces a clear increase in intracellular versican pro-
tein (Fig 3).
When looking at macrophages with different forward scatter signals we noted that cells with
high forward scatter (large macrophages) gave a higher specific mean intensity compared to
cells with a low forward scatter (small macrophages). To analyse this, the macrophage popula-
tions were divided into 3 separate regions (R3-R1) on the basis of increasing forward scatter
(FSC), as shown in Fig 3A and 3D. The proportion of cells in each of these regions differed in
normoxia and hypoxia (Fig 3B and 3E), likely reflecting the inhibitory effect of prolonged hyp-
oxia on the increase in cell size which is associated with macrophage maturation [40]. In both
normoxia and hypoxia, increasing cell size (forward scatter) significantly correlated with in-
creasing versican expression (Fig 3C and 3F). Comparison of R1 for normoxic and hypoxic
Fig 2. Assessment of versicanmRNA decay in HMDM in normoxia and hypoxia by real-time RT-PCR
after addition of Actinomycin D. N: normoxia 20.9%O2, H: hypoxia 0.2%O2. Data were normalized to 2MG
mRNA levels. Data from 5 independent experiments are expressed as means ± SEM.
doi:10.1371/journal.pone.0125799.g002
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macrophages (Fig 3G) demonstrates a statistically significant overall increase in versican pro-
tein expression of approximately 3 fold (Fig 3H). Similar hypoxia-induced increases in versican
mean fluorescent intensity were also observed in the smaller macrophages in regions R2 and
R3 (Fig 3F).
Very low levels of versican protein expression, and no hypoxic induction, were detected in
the lymphocyte population (R4; Fig 3C and 3F), which correlates well with the low versican
mRNA level, and relatively low and non-significant hypoxic induction observed in lympho-
cytes (Fig 1B).
Fig 3. Quantitation of versican protein expression in monocytes / macrophages by flow cytometry. (A and D) Dot plot analysis of PBMC after 5 days
in normoxia (20.9% O2; A) and hypoxia (0.2%O2; D). Monocyte/macrophages are subdivided into 3 regions R3-R1 in respect of increasing cell size (forward
scatter). Lymphocytes are included in region 4. Region 5 encompasses all monocyte macrophages in Regions 1, 2, and 3. A representative example of 5
independent experiments is shown. (B and E) Percentage of the total monocyte/macrophage population (R5) present in regions R1, R2, and R3 in normoxia
(B) and hypoxia (E). Data from 5 independent experiments are expressed as means ± SEM. (C and F) Versican mean fluorescent intensity in regions 1, 2, 3
and 4 in Normoxia (C) and Hypoxia (F). Data from 5 independent experiments are expressed as means ± SEM. (G) Histogram of the fluorescent intensity
with a versican specific antibody (black fill) compared to the isotype control antibody (white line) in region R1 cells in Normoxia and Hypoxia. A representative
example of 5 independent experiments is shown. (H) Histogram analysis of the versican fluorescent intensity in region R1 cells in Normoxia (shaded) and
Hypoxia (clear). A representative example of 5 independent experiments is shown. (I) Versican protein fold induction in cells region R1 in normoxia and
hypoxia. Data from 5 independent experiments are expressed as means ± SEM. For panels B, E, C, F, and I, the normoxic value in each experiment was
assigned an arbitrary value of 1. Data were further analyzed using two-tailed, paired t-tests. ** p < 0.01,* = p <0.05.
doi:10.1371/journal.pone.0125799.g003
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Deletion analysis of the versican promoter
To investigate the possible mechanisms of hypoxic up-regulation of the versican promoter, we
carried out a search of the proximal promoter region (-56 to +184; Fig 4A) for putative binding
sites for hypoxia-inducible transcription factors, using Genomatix Matlnspector and TESS
software. The -56+184 region of the versican promoter was chosen for analysis because it has
previously been shown to constitute a functional promoter and contains a typical TATA
box and has putative binding sites for a number of transcription factors including CREB, AP-1
and SP1 [35, 45]. An analysis of this sequence using Matinspector software identified a putative
binding site at +60 for the transcription factor Hypoxia-inducible factor-1 (HIF-1) (Fig 4A).
This putative HIF-1 site or Hypoxia Response Element (HRE) [46] was not identified in the
initial report of versican hypoxia responsiveness [25]. To analyse whether parts of this proxi-
mal promoter region are required for high level activity of the versican promoter in hypoxia,
we generated a series of deletion constructs in a luciferase reporter plasmid (Fig 4B) and trans-
fected them into HMDM. Promoter constructs containing the sequences -56+184, -56+154
and -56+104 (all containing the putative HIF-1 site at +60) show high levels of expression in
both normoxia and hypoxia (Fig 4C). Luciferase activity dropped markedly in the -56+54 con-
struct, indicating that the region +54 to +104, which includes the putative HIF binding site at
Fig 4. Activity of versican promoter luciferase reporter constructs in normoxia and hypoxia in HMDM. (A) Putative transcription binding sites for
hypoxia inducible factor (HIF), cAMP responsive element binding (CREB), activator Protein 1 (AP1), SP1, nuclear factor 1 (NF-1) and E2F within the 240 bp
(-56+184) versican promoter sequence. The -56 to -26 and +54 to +104 sequences which are important for high level expression are in bold. (B) Schematic
diagram of versican promoter or random 26mer luciferase reporter constructs used. (C) activity of versican promoter or random 26mer luciferase reporter
constructs in HMDM after 5d incubation in normoxia (20.9%O2), or hypoxia (0.2%O2). Data from an average of 6 independent experiments with each
construct, minimum n = 3 for each construct, are expressed as means ± SEM. Luciferase data were normalized to protein levels. Data assessed for
significant increase in hypoxia compared to random construct control using two-tailed t tests, *** = p <0.001 ** p < 0.01,* = p <0.05, ns = not significant.
doi:10.1371/journal.pone.0125799.g004
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+60bp, is important for high level expression of these versican promoter constructs in both
high and low oxygen concentrations. However, hypoxic induction (5.7 fold) was still observed
with the -56+54 construct, despite its lack of a HIF site. Fig 4C also shows that luciferase ex-
pression is markedly lower in constructs beginning at -26 (regardless of whether they contain
the putative +60 HIF site or not) compared to those beginning at -56, indicating that the region
from -56 to -26 encompasses a separate region required for high level activity of these versican
promoter reporter constructs.
Role of HIF-1 in hypoxic induction of versican expression in HMDM
To investigate whether the putative HIF binding site at +60 is responsive to HIF-1, we over-ex-
pressed HIF-1α in normoxic HMDM transfected with the -56+184 versican promoter lucifer-
ase reporter construct. As Fig 5A shows, HIF-1α over-expression did not affect the expression
of this construct, in contrast to marked up-regulation of the control PGK-1 reporter construct
which is known to be regulated by HIF-1 [47, 48, 49].
We also investigated the role of HIF-1 in endogenous versican mRNA expression. Previous
studies have shown that treatment of normoxic macrophages with LPS induces HIF-1αmRNA
and protein, and consequently HIF-1 inducible genes including Vascular Endothelial Growth
Factor (VEGF) [50, 51]. VEGF up-regulation by LPS has been shown to be dependent on HIF-
1 up-regulation [52, 53]. We treated normoxic HMDMwith LPS and quantified VEGF and
versican mRNA levels. As expected, LPS induced the mRNA of the HIF-1-up-regulated gene
VEGF (Fig 5B), however it did not induce versican mRNA in the same samples (Fig 5C), sug-
gesting that HIF-1 up-regulation alone (in the absence of other factors such as hypoxia itself) is
not sufficient for significant induction of versican.
To further elucidate the role of HIF-1 in the hypoxic induction of versican gene expression,
HMDMwere treated with the “hypoxia mimetic” agents Desferrioxamine (DFO) and CoCl2.
DFO and CoCl2, which are chemically unrelated, act via different mechanisms to stabilise the
hypoxia-inducible α subunit of HIF-1 in normoxia, leading to induction of HIF-1 dependent
hypoxia-inducible genes [54, 55, 56]. Among the genes they induce are VEGF and GLUT-1
[57, 58, 59]. Determination of versican, VEGF and GLUT-1 mRNA levels by real time RT-PCR
showed that as expected, 18h hypoxia induced versican (15.5-fold), VEGF (11.7-fold) and
GLUT-1 mRNA (15.5-fold) (Fig 5D). Similarly, DFO also induced versican mRNA expression
in normoxia (10-fold), and VEGF (11-fold) and GLUT-1 (29.5-fold), in the same RNA samples
(Fig 5E). In contrast, CoCl2 markedly induced VEGF (10.6-fold) and GLUT-1 mRNAs
(6.3-fold) but not versican mRNA, in the same RNA samples (Fig 5F).
Since cobalt chloride is known to induce HIF-1 protein and consequently expression of
HIF-1 controlled genes [60], the data indicate that versican is regulated differently to VEGF
and GLUT-1, via mechanisms which can be activated by hypoxia and DFO but not by CoCl2,
again suggesting that HIF-1 is not sufficient in itself to induce the versican promoter. There-
fore, we compared the level of HIF-1α protein (Fig 6A) with versican (Fig 6B) and the classical
HIF-1 regulated gene GLUT-1 (Fig 6C) mRNA levels after 5 days in normoxia, or after 4 days
in normoxia followed by 1 day of hypoxia, or after 5 days of continuous hypoxia. Versican
mRNA levels did not correlate closely with the levels of HIF-1α protein, being significantly
higher after 5 days, in contrast to the mRNA level of GLUT-1. These results cannot be ex-
plained by versican mRNA having greater stability in hypoxia than GLUT-1 mRNA, as Fig 2
showed that the reverse is true: GLUT-1 mRNA is marginally more stable than versican
mRNA in both normoxia and hypoxia. The data therefore suggest that versican hypoxic
mRNA levels may be responsive to factors other than HIF-1.
Hypoxic Up-Regulation of Versican Gene Expression in Macrophages
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Fig 5. Investigation of the role of Hypoxia Inducible Factor 1 (HIF-1) in versican up-regulation. (A) Effect of over-expression of HIF-1α on the 240 bp
(-56+184) versican promoter construct in HMDM. PGK was used as a positive control and pGL4 basic as a negative control. (B and C) Real time-PCR
analyses showing VEGF and versican mRNA fold induction after treatment with two different preparations of LPS (MINN LPS, Salmonella Minnesota LPS;
SAE LPS, Salmonella abortus equii LPS) in comparison with hypoxia. (D) Real time-PCR analyses show versican, VEGF, and GLUT-1 mRNA fold induction
in hypoxic and normoxic HMDM. (E)Real time-PCR analyses of versican, VEGF, and GLUT-1 mRNA fold induction in HMDM treated with cobalt chloride
(COB). N: normoxia 20.9%O2, H: hypoxia 0.2%O2. All incubations, with or without hypoxia, were for 18hrs. Data were normalized to 2MGmRNA levels.
Data from 3 (A, B, and C) or 5 (D and E) or 8 (F) independent experiments are expressed as means ± SEM. Data were further analyzed using paired two-
tailed t-tests. *** = p <0.001 ** p < 0.01,* = p <0.05
doi:10.1371/journal.pone.0125799.g005
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Fig 6. Immunoblotting shows lack of correlation between HIF-1α protein level and versicanmRNA up-
regulation by hypoxia. (A) After incubation under the conditions indicated, cell lysates were prepared from
HMDM and immunoblotted for HIF-1α and actin. A blot representative of 3 independent experiments is
shown. (B and C)Real time-PCR analyses show versican and GLUT-1 mRNA fold induction after 5 days of
normoxia, 4 days of normoxia followed by 1 day of hypoxia, or 5 days of hypoxia. N: normoxia (20.9%O2), H:
hypoxia (0.2%O2). Data were normalized to 2MGmRNA levels. Data from 3 independent experiments are
expressed as means ± SEM. The normoxic value in each experiment was assigned an arbitrary value of 1.
Data were further analyzed using two-tailed, paired t-tests. *** p< 0.001
doi:10.1371/journal.pone.0125799.g006
Hypoxic Up-Regulation of Versican Gene Expression in Macrophages
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Role of the PI3k—β-catenin pathway in hypoxic induction of versican
expression in HMDM
Data from the above experiments using CoCl2 and DFO suggested involvement of a signalling
pathway which can be activated by hypoxia and DFO but not by CoCl2. One such pathway is
known, involving PI3-kinase regulation of the transcription factor β-catenin. Hypoxia [61] and
DFO [62, 63] have been demonstrated to up-regulate this PI3K—β-catenin pathway, whereas
cobalt chloride down-regulates it [64]. Moreover, versican has previously been shown to be up-
regulated by the PI3K—β-catenin pathway [65]. To investigate the possible role of the PI3K
pathway in hypoxic up-regulation of versican, HMDMwere treated with two distinct specific
inhibitors of PI3K, LY290042 and wortmannin. These treatments resulted in significantly re-
duced hypoxic inductions (Fig 7). In contrast, PI3-Kinase inhibitors did not affect induction of
GLUT-1, a classical HIF-1 regulated gene. These data suggest a possible role for PI3-Kinase in
hypoxic up-regulation of versican mRNA in HMDM.
Discussion
Versican, an abundant and widely expressed extracellular matrix proteoglycan, has important
roles in a number of pathological conditions including cancer and atherosclerosis [30, 31,32,
33,34, 37, 38], in which accumulation of macrophages in hypoxic sites is a feature. In the pres-
ent study we aimed to characterize the expression of versican by macrophages and examine the
mechanisms responsible for its hypoxic induction.
Interestingly, our data show that in human monocyte-derived macrophages (HMDM), ex-
tended periods of hypoxia (5 days) produce far higher versican mRNA fold inductions (over
500 fold on average) than have been previously reported following 1 day of hypoxia (40 fold
[20]). This is of crucial biological relevance because macrophages entering hypoxic tissues such
as tumours, wounds and atherosclerotic plaques, where they accumulate in very high numbers,
remain there for extended periods [58, 16]. Thus, the degree of up-regulation of versican in
such sites, and the role played by hypoxia in versican upregulation in pathological sites, is likely
to be considerably more significant than previously appreciated. Our data also show that these
Fig 7. Real Time RT-PCR analysis of the effect of PI3K inhibitors on induction of versican and GLUT-1
mRNAs by 18h of exposure to hypoxia (0.2% O2). LY290042 was used at 2μM and wortmannin at 300μM.
^^; p<0.05 compared to DMSO control, *; p<0.05 compared to untreated control, ratio paired t test, one tailed.
Data from 5 independent experiments using HMDM from different donors, expressed as means ± SEM.
doi:10.1371/journal.pone.0125799.g007
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large increases in expression are observed for all detectable versican splice variants (V0, V1 and
V3; Fig 1C).
Actinomycin D mRNA decay experiments demonstrated that hypoxic induction of versican
mRNA in macrophages does not occur via changes in mRNA stability in hypoxia, since mRNA
decay did not differ between 0.2% and 20.9% O2, indicating that versican mRNA induction by
hypoxia occurs by transcriptional up-regulation (Fig 2).
We also investigated hypoxic up-regulation of versican at the protein level. Intracellular
FACS analysis of PBMC showed induction of versican protein in human monocyte/macro-
phages after 5 days in hypoxia, albeit at a much lower fold induction than for the mRNA, and
showed that versican protein production is specific to monocyte-macrophage lineage cells and
is not detectable in lymphocytes (Fig 3).
Asplund et al. [25] presented evidence which they believed implicated the hypoxia-inducible
transcription factor HIF-1 as being involved, at least in part, in hypoxic up-regulation of versi-
can. Co-localisation of versican and HIF-1α was reported in immunostained serial sections of
human carotid lesions. However, this is data does not prove a direct link: many other hypoxia-
inducible transcription factors and other hypoxia-inducible proteins also co-localise in hypoxic
sites, regardless of their mechanism of up-regulation. Therefore, we decided to investigate the
possible role of HIFs in versican hypoxic up-regulation in more detail. Asplund et al. reported
a conserved putative HIF-1 binding site in the +2871 to +2888 region of the versican gene in 7
species. We performed a more wide-ranging search of 37 species in the ENSEMBL database,
which shows that although some species do indeed possess a putative HIF-binding Hypoxia
Response Element (HRE) in or near this position, a majority (22/37) either have a very weak
consensus HIF site (2/37) or no HIF site (20/37). The finding that the majority of species
which could be analysed do not contain a HRE at this site weakens the evidence for this being a
functionally conserved transcription factor binding site, and suggests that it may be simply a
chance occurrence or a contributory rather than an essential site of predominant importance.
Anti-HIF-1α siRNA experiments carried out by Asplund et al using the THP-1 monocytic leu-
kemia cell line showed only a minor reduction in versican mRNA in hypoxia (approximately
20%) compared to approximately 40% reduction for the known HIF-1 regulated gene Glut-1.
This data led Asplund et al [25] to suggest that versican may be only partly regulated by HIF-1.
Their HIF-2α siRNA experiments produced a 27% knock-down in hypoxic versican mRNA
levels, and combined HIF-1α and HIF-2α siRNA showed only 44% reduction in versican
mRNA. Overall, given that macrophages have long been known to rely heavily on HIFs for en-
ergy production under both normoxia and hypoxia because of their dependence on glycolysis
[19], many mRNAs are likely to be down-regulated non-specifically and indirectly by siRNA
knockdown of HIFs. The specificity of the modest reductions in hypoxic versican mRNA levels
observed in the Asplund et al. siRNA experiments cannot be confirmed without suitable con-
trols, such as the demonstration that a gene which is known to be HIF-independent is unaffect-
ed by siRNA treatment. Since no such controls were shown [25], these data are not conclusive.
To investigate the regulation of versican transcription in HMDM, we cloned the -56 to +184
versican promoter sequence previously identified as constituting a functional promoter [35,
45] into the luciferase reporter plasmid pGL4. Analysis of this promoter sequence revealed
binding sites for a number of transcription factors which are known to be hypoxia-inducible:
CREB and AP-1 at -34, AP-1 at -4, SP1 at +25, HIF-1 at +60, E2F at +80 and NF1 at +94 (Fig
4A). We made a series of promoter deletion reporter constructs and transfected them into
HMDM. In general, promoter activity was higher in hypoxia than in normoxia (Fig 4C), how-
ever overall fold induction (H/N ratio) did not vary greatly between mutants. Promoter activity
was lower in the -56 to +54 construct compared to constructs containing the region +54 to
+104, indicating that the +54 to +104 sequence is crucial for high level versican promoter
Hypoxic Up-Regulation of Versican Gene Expression in Macrophages
PLOS ONE | DOI:10.1371/journal.pone.0125799 June 9, 2015 11 / 19
activity in both normoxia and hypoxia (Fig 4B). The data also showed that promoter activity is
markedly reduced in constructs which lack -56 to -26, suggesting that this region also contains
binding sites for transcription factors which are important for versican promoter activity in
HMDM. Overall, the data indicate that both the -56 to -26 and +54 to +104 regions are re-
quired together in the same construct for high expression from these versican promoter con-
structs in HMDM.
These observations suggest two alternative mechanisms: either two or more independent
transcription factors bind at these two sites, and are necessary for high level transcription, or
factors binding in these two regions interact to facilitate transcription; candidates include AP-1
(-34 and -4) which can interact with NF-1 (+94) [59] or CREB (-34) which could interact [66]
with the putative binding site we have identified at +60 for HIF-1, a transcription factor which
has previously been suggested [25] to play a role in versican hypoxic induction.
To examine the functionality of this putative HIF-1 binding site, we cotransfected the -56
+184 versican promoter construct with a HIF-1α over-expression construct; however, no in-
duction was observed, in contrast to the HIF-1 responsive control PGK-1 construct which was
strongly induced (Fig 5A).
To further elucidate potential role of HIF-1 in hypoxic up-regulation of versican, we exam-
ined induction of versican mRNA in HMDM. Previous studies [50, 51] have shown that HIF-
1αmRNA and protein are up-regulated by lipopolysaccharide (LPS) in monocyte-macrophage
lineage cells. Our data show that treatment of HMDMwith LPS from two different bacterial
species did not significantly induce versican mRNA, in contrast with the mRNA of VEGF,
which is known to be up-regulated by LPS via a HIF-1-dependent mechanism [50] (Fig 5B and
5C). In addition, we treated HMDMwith cobalt chloride and Desferrioxamine (DFO). These
“hypoxia mimetic” agents act via different mechanisms to stabilise HIF-1α, increasing HIF-1
protein levels in normoxia, and up-regulating the expression of HIF-1 dependent hypoxia-in-
ducible genes [54, 55, 56, 60]. Both hypoxia and DFO up-regulated versican and the two con-
trol HIF-1 dependent genes VEGF and GLUT-1. In contrast cobalt chloride up-regulated
VEGF and GLUT-1 but not versican mRNA (Fig 5D–5F). Taken together, the lack of induction
of versican mRNA by LPS and cobalt chloride, two stimuli which are known to strongly up-
regulate HIF-1α and thus HIF-1-regulated gene expression, suggest that versican is up-regulat-
ed differently to VEGF and GLUT-1, either via a mechanism in which HIF-1 alone is not suffi-
cient or via a HIF-1 independent mechanism.
The ability of DFO, but not cobalt chloride, to up-regulate versican mRNA suggested the
possibility of a hypoxic induction pathway involving up-regulation of β-catenin by PI3K, be-
cause this pathway is known to regulate versican expression [65], and to be induced by hypoxia
and DFO [61, 62] but not induced by cobalt chloride [64]. To test this hypothesis we treated
HMDMwith two distinct PI3K inhibitors, LY290042 and wortmannin, and showed that both
caused a marked reduction in hypoxic induction of versican while having no effect on hypoxic
induction of the classic HIF-1 regulated gene GLUT-1 (Fig 7). These data provide evidence of a
role for PI3K in the hypoxic induction of versican in HMDM. Based on the previous work of
Rahmani et al., [65], this could be mediated via the stimulatory effects of PI3K on β-catenin.
This concurs with the evidence of our promoter deletion studies, in which even a very minimal
reporter construct (-26 to +54) was inducible by hypoxia (Fig 4), since there is an AP-1 binding
site at position -4, and β-catenin has been shown to be able to mediate transcriptional up-regu-
lation through AP-1 sites, in combination with TCF/LEF and ATF transcription factors [67].
In addition to the previously determined ability of β-catenin to regulate the versican promoter
by modulating TCF/LEF transcription factor activity [61], a recent study by Yang and Yee
et al., [68] has reported a novel versican- β-catenin control mechanism involving shared regu-
latory miRNAs. Precise delineation of the potential role of PI3K in hypoxic induction of
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versican, which has been highlighted in this study, and its relative importance, merits further
investigation.
Materials and Methods
Ethics Statement
Blood for preparation of peripheral blood mononuclear cells was obtained from healthy volun-
teer donors. Informed written consent was obtained from all donors and the study was ap-
proved by the local research ethics committee of the Department of Infection, Immunity and
Inflammation, University of Leicester, Leicester, UK.
Isolation and hypoxic culture of peripheral blood mononuclear cells
(PBMC) and human monocyte derived macrophages (HMDM)
PBMC were isolated from heparinised (10 U/ml) blood by centrifugation on Ficoll-Paque Plus
(Amersham Biosciences, Little Chalfont, UK) according to the manufacturer’s instructions.
Cells were resuspended at a density of 1 × 106 cells/ml in Iscove’s-modified Dulbecco’s medium
(Sigma, Poole, UK) supplemented with 2.5% human AB serum (BioSera, UK), 2 mM L-gluta-
mine (Sigma, UK), 200 U/ml penicillin and 200 μg/ml streptomycin (Sigma, UK). For Real
Time PCR experiments, PBMC were cultured in 2ml at a cell density of 2×106 per well in 6
well plates (Nunclon) and for FACS experiments they were cultured in 6 well Costar ultra low
attachment plates (Corning, USA). Adherence-purified Human Monocyte Macrophages
(HMDM) in 6 well plates (Nunc) were obtained as previously described [21] by allowing
PBMC to adhere to wells for 2 hours at 37°C. Non-adherent cells were removed by medium
changing. The adherent monocytes were then incubated for 5 days in 37°C to allow differentia-
tion into macrophages. For transfection experiments, PBMC were cultured in a volume of 4 ml
at a density of 1×106 cells per ml in 6 well in ultra low attachment plates and then cultured for
5 days to allow differentiation of monocytes into macrophages. CD14-microbead-purified
monocytes were prepared using CD14 microbeads and MS isolation columns fromMiltenyi
Biotec (Bisley, UK), following the manufacturer’s instructions, and cultured in 6 well adherent
plates at a cell density of 1x106 cells /ml, in 2 ml /well. Cells which passed through the column
were designated CD14- cells and were found to be typically>95% lymphocytes as assessed by
FACS analysis. Cells were cultured under normal oxygen concentrations (normoxia) in a hu-
midified atmosphere of 95% air (20.9% O2), 5% CO2, which, allowing for partial pressure of
water vapour, equates to 18.6% O2 (141 mmHg), or under hypoxia in a humidified multi-gas
oxygen control Galaxy R incubator (New Brunswick Scientific, UK) containing 5% CO2, 94.8%
N2, and 0.2% O2 (1.5 mmHg). Oxygen levels indicated on the incubator display screens were
verified using a separate oxygen meter (Analox, UK).
Actinomycin D treatment
For mRNA half-life analysis, in order to block further transcription, Actinomycin D (Sigma) at
a final concentration of 10μg/ml was added to 2 × 106 adherent HMDM after incubation for 5
days in either normoxia or hypoxia. Cells were then incubated under normoxia or hypoxia for
the required times prior to RNA isolation.
LPS, Cobalt chloride and Desferrioxamine treatment
After 5 days incubation under normal oxygen tensions, 2 × 106 adherent HMDMwere treated
with Salmonella abortus equii lipopolysaccharide (Alexis Biochemicals, Lausen, Switzerland)
or Salmonella minnesota lipopolysaccharide (Sigma) at 100 ng/ml and incubated under
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normoxia or hypoxia for the required time prior to RNA isolation. Cobalt chloride (Sigma)
was added to cell culture medium at a final concentration of 300 μM, and Desferrioxamine
(DFO; Sigma) was added at a final concentration of 200 μM.
PI3K inhibition
Cells were treated with LY290042 (Sigma) at final concentration of 2μM and wortmannin
(Sigma) at a final concentration of 200nM. Inhibitors were dissolved in DMSO (Sigma).
RNA isolation and real-time RT-PCR
RNA was isolated using TRI reagent (Sigma) according to the manufacturer’s instructions. Re-
verse transcription was carried out as previously described [62]. Reverse transcription products
were amplified in a 20 μl reaction mix containing 1 × SYBR Green Taq ReadyMix Capillary
Formulation (Sigma) and the required forward and reverse primers.
Versican primer sequences were derived from NCBI nucleotide bank accession no.
NM_004385. Forward primer 50-ACAAGCATCCTGTCTCACG-30 is from nucleotides 9879–
9897; reverse primer 50-TGAAACCATCTTTGCAGTGG-30 is from nucleotides 10254–10273.
β2MG[18]: Fwd50-GGCTATCCAGCGTACTCCAAAG-30; Rev 50-CAACTTCAATGTCGGATG
GATG-30. GLUT-1 and VEGF primers are as previously described [21]. Amplifications were
carried out on a Roche LightCycler Real-time PCR instrument (Mannheim, Germany) using
the following cycling parameters: pre-incubation at 95°C for 10 min then 45 cycles of 96°C for
10 sec, 60°C for 10 sec, 72°C for 25 sec. All reactions were finished with a melting curve run to
establish specificity. PCR data were normalized to the relative concentration of β2-microglobu-
lin (β2MG) housekeeping gene mRNA determined by separate PCR on each sample [40]. In
contrast to versican mRNA levels, which were highly up-regulated by hypoxia, β2MGmRNA
levels in HMDMwere not markedly affected by the hypoxic conditions used (0.2% O2 for up to
5 days), as we also reported in a previous study [40], in which we also found that β2MG levels
correlated closely with total RNA quantification values.
Generation of versican promoter reporter constructs
A 240-bp (-56/+184) versican promoter sequence and shorter versions thereof were generated
by PCR from human genomic DNA with the appropriate sets of primers based on the pub-
lished versican promoter sequence ([45], accession number U15963; primer sequences avail-
able upon request). These inserts were cloned into the SfiI site of the pGL4.10 [luc2] luciferase
reporter plasmid (Promega) using standard techniques. A 29 bp random nucleotide sequence
(CTAGCTAGCTAGCTAGCTAGCTAGCTAGC) was generated and also cloned into pGL4.10
[luc2] for use as a negative control in transfection experiments. All constructs were verified
by sequencing.
Transfection and Luciferase Activity Assays
PBMCs were transiently transfected with μg of reporter plasmid DNA using JetPEI transfection
reagent (Polyplus) according to the manufacturer’s protocol. Transfected cells were plated at
2×106 cells per well in 6 well plates (Nunc). After 1hr in normoxia at 37°C, cells were incubated
under both normoxia and hypoxia as described above for a further 5 days prior to luciferase
assay. For HIF-1α over-expression, PBMCs were transfected with 1ug of 240bp (-56 to +184)
versican luciferase reporter construct, Phosphoglycerate kinase-1 luciferase reporter construct
(PGK; constructed as described by Ameri et al., 2002) or empty pGL4.10 [luc2] plasmid (Pro-
mega). Cells were co-transfected with 300ng of HIF-1α over-expressing plasmid (pCDNA3.1/
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HIF-1α; a kind gift from Professor Chris Pugh, University of Oxford)) or the negative control
plasmid (pCDNA 3.1 CAT) for 24 h in normoxia prior to luciferase assay. After incubation in
either normoxia or hypoxia, medium was removed and cells were washed twice with 1xPBS.
Cells were then lysed, and luciferase activities were quantified using luciferase assay reagents
(Promega) according to the manufacturer’s protocol. Protein concentrations were measured
using a Bradford assay (Thermo Scientific) and luciferase values were normalized to the ob-
tained protein concentrations.
Intracellular FACS analysis of versican protein expression
Based on previous work on quantitation of versican protein expression using FACS [44],
HMDMs were incubated in low attachment plates (Costar) for 4 days under the appropriate
oxygen tension, then incubated under the same oxygen tension for a further 24h in the pres-
ence of 2μg/ml Brefeldin A (B6542, Sigma) to block protein secretion prior to quantification of
protein by FACS. Therefore the versican detected will represent newly synthesized protein, but
possible contribution of some versican taken up from the cell supernatant can not be ruled out.
Cells were fixed using 1% paraformaldehyde and permeabilised with 0.1% saponin (Sigma) in
PBS, washed twice with PBS/2% FCS and incubated with monoclonal anti- human versican an-
tibody (MAB3054, R&D Systems) or rat IgG1 isotype control (MAB005, R&D Systems) at 1:50
dilution on ice for 45 min. Cells were then washed and incubated with 1:40 diluted FITC conju-
gated anti-rat IgG (F1763, Sigma) on ice for 45 min. After washing, cells were acquired on a
FACSCalibur flow cytometer and analyzed with CellQuest software (Becton Dickinson).
Western Blots
Cells were detached from culture plates by scraping, pelleted at 400 g for 1 min at 4°C, resus-
pended in 4 volumes of ice cold lysis buffer (50mM Tris pH8, 280mMNaCl, 0.5% NP-40,
0.2mM EDTA, 2mM EGTA, 1mM PMSF, 0.1mMNa3VO4, 1mM DTT, 1μg/ml Leupeptin,
2μg/ml Aprotinin, and 1μg/ml Pepstatin—all reagents from Sigma), and incubated on ice for 5
min prior to storage at -80°C. Samples were assayed for protein using the DC protein assay kit
(BioRad, UK). Ten micrograms of protein was loaded onto Tris-glycine SDS page gels and elec-
trophoresed and immunoblotted using specific antibodies at 1:250 dilution (HIF-1α: Trans-
duction Laboratories Cat. No. 610959, Mouse monoclonal, Clone 54; Actin: Sigma Cat. No. A-
2066, Rabbit polyclonal) as previously described [18].
Database analysis
The versican promoter sequence was searched using Matlnspector (Genomatix, http://www.
genomatix.de/online_help/help_matinspector/matinspector_help.html) and Transcription El-
ement Search System (TESS) software (http://www.cbil.upenn.edu/cgi-bin/tess/tess?RQ=
WELCOME).
Statistics
Analyses were performed using GraphPad Prism, GraphPad Software Inc., San Diego, USA.
Results were considered significant if p 0.05 (, p 0.0001; , p 0.001; , p 0.01;
and , p 0.05, ns = not significant).
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